We observe significant reductions in two Th1 (IFNγ and IL-12p70) and four Th17 (IL-17, IL-21, IL-23, and IL-1β) proinflammatory cytokines as early as day 8 post-AHSCT in the MS cohort, with persistent reduction in these cytokines out to 3 months. The gene discussed is IL17A; the disease is myeloid sarcoma.